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Aortic stenosis (AS) and mitral regurgitation (MR) account for the majority of valvular diseases and their prevalence is increasing
accordingtoincreasedlifeexpectancy.Surgicaltreatmentisthegoldstandard,althoughoperativeriskmaybehighinsomepatients
due to comorbidities and age. A large part of the patients at high surgical risk who could beneﬁciate of treatment are not referred
to surgery. Therefore, there is a need of alternative and less invasive procedures.
1.Introduction
Valvular heart disease is nowadays a relevant cause of
morbidity and mortality. Aortic stenosis (AS) and mitral
regurgitation (MR) account for the majority of valvular
diseases and their prevalence is increasing according to
phenomenon of population ageing [1, 2].
Surgery (aortic valve replacement for the AS and mitral
valve repair or replacement for MR) is the gold standard
treatment and warrants good and reproducible clinical and
functional outcomes in most patients, although operative
risk may be high in some patients due to comorbidities and
age. Several registries revealed that up to 50% of the patients
with severe valvular disease, even if a surgical indication
existed, are not referred to surgery and the main reasons
of this are a high operative risk, multiple comorbidities
and advanced age [3, 4]. Thus, surgery is denied for a
relevant number of patients who could beneﬁciate of it.
Therefore, there is a need of alternative and less invasive
procedures. The target of these novel minimal invasive tech-
niques is to provide results similar to those of conventional
surgery in terms of eﬃcacy, safety, and durability. Over the
past years several techniques for percutaneous repair and
implantation have been developed. This paper provides an
overviewoftheseemergingapproachesoftranscathetervalve
repair/implantation procedures.
2. Percutaneous Aortic Valve Therapy
Aortic stenosis is currently the most common valvular dis-
ease in the Western population, with a prevalence of 4.6% in
adults ≥75years[3,5].Theneedforaorticvalvereplacement
(AVR) will continue to escalate according to the increase
in life expectancy [6]. Surgical AVR has been performed
since the early 1960s and is currently the standard treatment
for patients with severe symptomatic AS, providing relief of
symptoms and improving survival (survival has been shown
to improve from 38% to 90% at 5 years following surgical
AVR) and quality of life, even in the very elderly group
[7–12]. Surgical AVR has an average operative mortality
of 3% to 8%, with an important variability primarily due
to patient characteristics, comorbidities, and reduced left
ventricular function [7, 8, 13, 14]. Several scoring systems
have been developed in order to help predict operative
mortality, such as the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) and the Society of
Thoracic Surgeons (STS) score [15, 16].
Patients with high EuroSCORE or STS score are often
deniedsurgery.Theadventoftranscathetertechnologiesmay
provide a desired alternative to medical management for
these high-risk patients.
Moreover,thefeasibilityoftheimplantationofapercuta-
neous aortic valve using the TAVI techniques (valve-in-valve2 Cardiology Research and Practice
Figure 1: The Edwards-Sapien balloon-expandable prosthetic
valve, constructed of a stainless-steel stent, bovine pericardial
leaﬂets and a fabric sealing cuﬀ.
concept) to treat patients with a degenerated bioprosthesis
previously surgically implanted has been recently demon-
strated [17, 18]. In the future, TAVI approach will likely
become an option not just for elderly or high-risk patients,
butalsoforyoungerpatientswiththeknowledgethatavalve-
in-valve procedure can be performed if degeneration occurs.
Thiscouldrevolutionizethetreatmentofaorticvalvedisease.
3. CurrentTechniques
First human implantation of a balloon-expandable percuta-
neous aortic valve (AV) was performed in 2002 by Cribier
et al. to treat a severe calciﬁed AS in a 57-year-old man
with prohibitive surgical risk [19]. Since then, thousands
of patients have undergone this procedure worldwide,
and at this time, eight years after this initial experience,
transcatheter aortic valve implantation (TAVI) is a primary
therapeutic modality for high-risk or technically inoperable
patients with critical AS.
In November 2007, a committee of experts including
members of EACTS and ESC deﬁned a consensus position
statement for TAVI procedures [20].
Two diﬀerent devices are under clinical investigation and
commonly used for TAVI.
3.1. Edwards-Sapien Prosthesis. The ﬁrst device is the
Edwards-Sapienvalve(EdwardsLifescience,Inc.,CA,USA—
Figure 1). It consists of three bovine pericardial leaﬂets
mounted within a balloon-expandable stainless-steel stent.
Current prosthesis sizes include 23 and 26mm. Current
devices require either 22F or 24F (transfemoral) or 26F
(transapical) sheath for delivery [21].
The Edwards-Sapien valve was ﬁrst implanted via the
antegradetransseptalapproachtotheleftatriumandpassage
through the mitral valve to reach the AV [19]. With this
approach there is a high risk of anterior mitral valve leaﬂet
injury, causing severe mitral regurgitation. Transfemoral
retrograde approach has been shown to be safer and is
now preferred [22–26]. Patients are usually placed under
Figure 2: The CoreValve self-expandable prosthetic valve, con-
structed of a nitinol stent, pericardial leaﬂets, and sealing cuﬀ.
general anesthesia with endotracheal intubation, although
sedation and analgesia may be suﬃcient. After crossing
the AV, a balloon aortic valvuloplasty (BAV) is performed
using standard techniques in order to predilate the stenotic
valve. Simultaneous rapid right ventricular pacing using
a temporary pacemaker (usually 180beat/min), decreasing
cardiac output, is used to stabilize the balloon during the
inﬂation. The percutaneous valve is then placed within the
aortic annulus, and when its position seems to be optimal,
it is released. Also the deployment of the valve is achieved
under rapid pacing. For the larger introducers (22F, 24F)
used with the Sapien valves, two 10Fr Prostar closure devices
are usually placed within the vessel before any introducer
sheathissited. Becauseofthelargedelivery system,asurgical
cutdown and repair of the vascular access site are still often
required [27].
Because of the large proﬁle of the device, many patients
with small or diseased iliofemoral arteries are not eligible
for the procedure. The minimal vessel diameter required for
sheath insertion in the transfemoral approach is 7 and 8mm
for the 22- and 24-F catheters, respectively, for the Edwards-
Sapien valve.
An alternative transapical antegrade approach has been
proposed, with good initial results [28–30]. Through a
left anterolateral minithoracotomy, with the patient under
general anesthesia, the pericardium is opened over the apex.
Temporary pacing wires are placed on the left ventricle (LV),
the LV apex is punctured, and 2 pledgeted sutures are placed.
As t i ﬀ wire is passed to the descending aorta, and BAV is
performed. The percutaneous valve is then deployed. For the
transapical approach, femoral access and cardiopulmonary
bypass should be on standby, to consent a rapid surgical
conversion in case of complications.
3.2. CoreValve Revalving System. The second device is the
CoreValve Revalving System (Medtronic, Inc., MN, USA—
Figure 2), which consists in three porcine pericardial leaﬂets
mounted in a self-expanding nitinol frame. The CoreValve
is available in 26 and 29mm sizes, going through an 18F
introducer, allowing smaller arterial diameters (6mm) in
respect to the delivery system of the Edwards-Sapien valve.
The total length of the valve is 50mm. It has a speciﬁc
design with a waist in the middle part. The lower part ofCardiology Research and Practice 3
the valve is designed to expand using high-radial forces. The
middle part includes the leaﬂets and is constrained to avoid
coronary occlusion, while the upper part enables ﬁxation in
the ascending aorta. The CoreValve is typically implanted
retrograde from the femoral artery.
A transaxillary approach has been proposed for the self-
expandable valve and it has been used also with the balloon-
expandable valve [31, 32].
Recently, for patients with “no-access options”, also a
transaortic approach through a ministernotomy access has
been described [33, 34]. The latest 3rd generation device
enables performance of the procedure without rapid pacing
[21, 24].
Whilst the Edwards system appears to have a greater
requirement for native valve calciﬁcation in order to anchor
the prosthesis, the CoreValve is self-expandable with a shape
that seems less likely to embolize, even within a valve
containing little calcium.
The positioning of the CoreValve is straightforward in
theory; however, the self-expanding nature of the valve
presents certain dynamism to the deployment process that
remains, on occasion, challenging. An advantage of this
device over the Edwards-Sapien valve, however, is that it is
fully retrievable as long as the introducer catheter is not
released from the valve. Once released, however, neither
device is retrievable.
4.PatientSelection
4.1. Surgical Risk. TAVI is indicated in patients with pure or
predominant severe AS, while the treatment of severe aortic
regurgitation is still an oﬀ-label indication for TAVI. The
most important issue in the selection of the candidates for
TAVI is the analysis of the surgical risk and the evaluation of
life expectancy. The decision-making process should involve
a multidisciplinary team composed by cardiologists, car-
diac surgeons, radiologists, and anesthesiologists. Physician’s
judgment in association with an assessment based on several
surgical risks score (expected mortality > 20% with Logistic
EuroSCORE and >10% with STS score) is the key element
to establish patients at high surgical risk. This approach
considers also factors that are not covered in the scores
but that may make surgery prohibitive, such as porcelain
aorta, previous CABG with patent graft, liver cirrhosis,
or neurological dysfunction. Age alone or simply refusal
of surgical intervention is not suﬃcient for indication to
TAVI instead of surgery. TAVI should not be performed in
patients presenting with a life expectancy <1y e a rb e c a u s eo f
extracardiac comorbidities [15, 16, 20, 35].
4.2. Anatomical Considerations. Once deﬁned the surgical
risk, feasibility of the TAVI procedure and exclusion of
contraindications should be assess.
C o r o n a r ya n g i o g r a p h yo rC Ts c a ns h o u l db ep e r f o r m e d
to evaluate the anatomy of the coronary arteries. However,
many of these patients have calciﬁed coronary disease, limit-
ing the value of CT scan. In case of need of revascularization,
the chronology and the modality of interventions should
be individualized based on the clinical status of the single
patients.
The correct sizing of the AV is the critical step to
establish the feasibility of the TAVI and to minimize the
risk of paravalvular leak or prosthesis migration after the
deployment. A gold standard method of measurement has
not been yet established. Echocardiography and CT scan are
both used [36–40].
The evaluation of the state of the peripheral access (size,
tortuosity, and calciﬁcation) is obtained by angiography or
CT scan [20, 41].
ThemostimportanttechnicalcontraindicationsforTAVI
are the inadequacy of the aortic annulus (<18mm or
>25mm for balloon-expandable prosthesis and <20mm or
>27mm for self-expandable), presence of asymmetric valvu-
lar calciﬁcation (because of the high risk of compression
of the coronary arteries), an ascending aortic dimension
>45mmatsinotubularjunctionfortheself-expandablevalve
and the presence of LV thrombosis [20, 23].
The choice of the correct approach (transfemoral or
transapical) should be discussed according to the patient
condition and local expertise. Speciﬁc contraindications
for transfemoral approach include inadequacy of femoro-
iliac arteries (severe calciﬁcation, tortuosity, or small diam-
eter, according to the device used or previous aorto-
femoral bypass), transverse ascending aorta for the balloon-
expandable device, and adverse aortic condition (severe
angulation, atheroma of the arch, and aneurysm of abdom-
inal aorta with protruding mural thrombus). Contraindi-
cations for transapical approach are previous LV surgery
(such as Dor procedure), severe respiratory insuﬃciency,
not reachable LV apex through thoracotomy, and calciﬁed
pericardium [20].
In patients presenting with an estimated extreme clinical
risk or because of anatomical inadequacy for TAVI, a
BAV procedure may be useful as a bridge to subsequent
percutaneous implantation or as palliation. No survival
beneﬁt has been showed after BAV [1–3, 42].
5. Results
Procedural success exceeds 90% in experienced centers.
Mortality at 30-days ranges from 5% to 18% [22–26, 43–
45]. The 30 day mortality reported in the SOURCE Registry,
which was designed to assess the initial clinical results of
the Edwards-Sapien valve in consecutive high-risk patients
in Europe, was6.3% in TF patients and 10.3% in TA patients
[46, 47]. The recently published Canadian experience with
the Sapien valve reported an overall 30-day mortality of
10.4% (9.5% for TF approach and 11.3% for TA approach)
andamortalityrateatameanfollowupof8monthsof22.1%
[44].
Incidence of stroke is 1.7%–2.5% and it seems to be
similar for both procedural approaches [44, 46].
The periprocedural death observed with the CoreValve
Revalving System is similar [43].
Vascular complications remain a signiﬁcant cause of
mortality and morbidity (incidence 10%–15%) [23, 44–46],
also if in the SOURCE Registry this type of complication was4 Cardiology Research and Practice
proved to be no longer a predictor of <30-day mortality in
the transfemoral approach [46]. Acute myocardial infarction
occurs in 2%–5% [46]. Coronary obstruction and pros-
thesis embolization are rare (<1%) [20, 24, 26, 48]. Mild-
to-moderate AR, without hemodynamic impairment, is
observed in about 50% of the patients, mostly para-valvular.
Signiﬁcant AR occurs in 2%–5% [24, 26, 43]. Finally, AV
block occurs in 4%–10%, necessitating pacemaker implan-
tation in up to 24% with self-expandable device [49–53].
Left bundle-branch block with left-axis deviation, interven-
tricular septal dimension >17mm, and noncoronary cusp
thickness >8mm were identiﬁed as predictors of AV block
and need of permanent pacemaker following placement of
self-expandable prosthesis [54].
6.O ur2-Y earExpe rie nc ewithT A VIin
High-RiskSurgicalCandidates
From November 2007, 137 patients with severe aortic steno-
sis underwent TAVI at our Institution, 64 females with mean
age 79 ± 7 years. Peak and mean aortic gradients were 88.2
± 25.4mmHg and 53.9 ± 15.7mmHg, respectively. Mean
Logistic EuroSCORE and STS-PROM score were 26.3 ± 16
and7 ±4.9,respectively.Patientshadmultiplecomorbidities
(Charlson score 6 ± 1.7). Baseline characteristics of the
patients are shown in Table 1.
An Edwards-Sapien valve was implanted in 79 patients
(61 transfemoral, 15 transapical; and 3 transaxillary); a
CoreValve was implanted in 58 patients (46 transfemoral
and 12 transaxillary). Procedural success rate was 99.2% (1
acute aortic dissection requiring emergent surgery). Hospital
mortality (30 days) was 3%. Postoperative complications
included vascular lesions (62 patients), renal failure (10
patients), need for PM (38patients), moderate to-severe-
aortic regurgitation (14 patients), and cerebrovascular event
(6patients).Meanlengthofstaywas9±9.8days(range2-to-
68days)(seeTable2).Followupwas100%complete(mean6
± 4 months). Actuarial 6-month survival was 89% ± 5% for
the combined experience and it was 73% ± 16%, 100%, and
91% ±4%forthetransapical,transaxillaryandtransfemoral
approaches, respectively (Tables 2 and 3).
7.PercutaneousMitralProceduresfor
the Treatment of Mitral Regurgitation
The development and evaluation of mitral valve (MV) repair
technologies represents an emerging challenge. Currently,
severalpercutaneousapproaches forthe treatment of MR are
in early clinical use or undergoing preclinical investigation.
Percutaneous repair of the MV has many diﬀerences com-
pared to TAVI procedures, in consideration of the diﬀerent
mechanismsthatcanleadtoMR(variableannulardilatation,
abnormal leaﬂet coaptation, abnormal chordal structure,
among others). One or more of the elements of the MV
apparatus may be involved according to the etiology of the
MR and the patient population may be very heterogeneous
for age and comorbidities [55].
Figure 3: The Mitraclip device is a two-armed, polyester-covered,
ﬁxation device. Each arm has an opposing gripper that aids the
leaﬂets in the clip by means of multipronged friction element.
ThemostadvancedpercutaneousMVrepairprocedureis
the Alﬁeri edge-to-edge repair using the Evalve Percutaneous
Mitral Repair System, also known as MitraClip device
(Evalve, Inc., CA, USA—Figure 3). The Alﬁeri repair consists
in suturing the free edge of the anterior mitral leaﬂet
to the free edge of the posterior leaﬂet at the site of
the regurgitation. The result is a double-oriﬁce valve with
improved leaﬂet coaptation. This surgical procedure has
proven early eﬃcacy and durability in various anatomic and
functional lesions [56–58]. The Mitraclip system reproduces
thesurgicalprocedureusingacliptojointhefreeedgesofthe
opposing leaﬂets [59]. This procedure involves transseptal
cannulation of the left atrium and positioning the delivery
system perpendicular to the MV. Under TEE guidance, the
clip is placed to appose the two mitral leaﬂets, creating a
double-oriﬁce valve. The reduction of the MR severity is
real-time assessed and, if necessary, it may be repositioned
to reduce MR further. The operator should be familiar
with echo imaging and a close collaboration between the
operator and the echocardiographist is mandatory to run the
procedure safely and eﬃciently. Live 3D echocardiography is
very helpful particularly for clip orientation and alignment
on the coaptation line. Final echo assessment should be done
under vasoconstrictors. When the result is satisfactory, the
clip is deployed and the delivery system is removed. In case
of persistent signiﬁcant MR (>2+/4+), a second clip may be
placed.
Recently, the feasibility of the procedure using conscious
sedation has been reported in [60].
8.PatientSelection
Patient selection is fundamental for the eﬃcacy of the proce-
dure. Indications for the Mitraclip are still preliminary and
will continue to evolve as the techniques and technologies
will prove eﬃcacy and safety. The best indication for the
endovascular edge-to-edge is given in those patients with
severedegreeofmitralregurgitationandwithsymptomsthat
areathighriskforsurgery.Fromapuretechnicalstandpoint,
the procedure is feasible only in a subgroup of patientsCardiology Research and Practice 5
Table 1: Clinical characteristics of patients presenting for transcatheter aortic valve implantation.
Transfemoral Transapical Transaxillary P value
Patients 107 15 15
Edwards-Sapien, n (%) 61 (57) 15 (100) 3 (20) <.0001
CoreValve, n (%) 46 (43) 12 (80) <.0001
Age (years) 79.7 ± 7 78.8 ± 6.5 78.7 ± 5 .794
Male, n (%) 56 (52) 5 (33) 12 (80) .034
Diabetes, n (%) 31 (29) 4 (26.7) 5 (33) .917
Chronic kidney disease, n (%) 39 (36.4) 5 (33) 7 (46.7) .706
Porcelain aorta, n (%) 17 (15.9) 14 (93.3) 7 (46.7) <.0001
COPD, n (%) 46 (43) 6 (40) 11 (73) .077
Previous myocardial infarction, n (%) 29 (27) 5 (33) 6 (40) .549
Cerebrovascular disease, n (%) 20 (18.7) 8 (53) 3 (20) .011
Peripheral vascular disease, n (%) 26 (24.3) 10 (67.7) 12 (80) <.0001
NYHA functional class III-IV, n (%) 75 (70) 11 (73.3) 9 (60) .685
Logistic EuroSCORE, mean ± SD 26.6 ± 16 32.2 ± 23 28.6 ± 14 .477
STS-PROM score, mean ± SD 7 ± 4.9 8.3 ± 4.2 6.9 ± 2.8 .602
Mean aortic gradient (mmHg), mean ± SD 54 ± 17.2 44.7 ± 18 47.7 ± 14.9 .074
LVEF (%), mean ± SD 50.8 ± 12.9 50 ± 12.5 52.8 ± 11 .814
COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; LVEF: left ventricle ejection fraction.
Coaptation
length
<2mm
(a)
Coaptation
depth
>11mm
(b)
Flail
gap
≥10mm
(c)
Flail width
≥15mm
(d)
Figure 4: Anatomical exclusion criteria for the percutaneous edge-to-edge repair.6 Cardiology Research and Practice
Table 2: Procedural and in-hospital results of patients submitted to
transfemoral TAVI approach in our Institution.
Patients (n) 107
Hospital stay, days (mean ± SD) 9.5 ± 1.4
Procedural success, n (%) 100 (93.5)
Vascular complications, n (%) 31 (29)
Need for permanent pacemaker, n (%) 19 (17.8)
Neurological event, n (%) 3 (2.8)
Acute renal failure requiring CVVH, n (%) 5 (4.7)
30-day clinical outcomes
Death, n (%) 1 (0.9)
Cardiac death, n (%) 0
LVEF, n (%) 52.6 ± 11.5
Six months cumulative clinical outcomes
Death, n (%) 12 (12.2)
Cardiac death, n (%) 2 (2.0)
LVEF (%), mean ± SD 53.22 ± 9.1
SD: standard deviation; CVVH: continuous veno-venous hemoﬁltration;
LVEF: left ventricle ejection fraction.
with speciﬁc anatomical characteristics and this makes the
eligibility limited (see Figure 4).
The ﬁrst step in the screening process to select patients
who could be eligible for the procedure is transthoracic
echocardiography, especially with regard to the parasternal
short-axis view of the mitral valve and origin of MR jet(s).
The main eligibility criterion is jet location.
Deﬁnitive patient selection is done by transesophageal
echocardiography. Mitral regurgitation should originate
from the middle of the valve (from A2–P2 segments).
The mechanism of regurgitation can be either a prolapse
or a restricted motion not related to rheumatic disease.
The discontinuation between the two leaﬂets at the site of
regurgitation should be minimal and the annular dilatation
and/or calciﬁcation should be absent or non relevant. In case
of prolapse, the jet width should be less than 15mm, and the
ﬂail gap less than 10mm. In case of functional MR, the jet
width should be again less than 15mm, and the coaptation
depth ideally should be less than 10mm, with the leaﬂets
having a minimal residual coaptation [61–63].
9. Results
The results phase I of the multicenter prospective trial
EVEREST (endovascular valve edge-to-edge repair study),
including 107 patients with central MR (21% with pure
functional MR) who were eligible for surgical MV repair
showed a periprocedural incidence of major events of
9%, including 1 nonprocedural death. Freedom from clip
embolization was 100%. Procedural success was achieved
in 74% of the patients, and 64% presented MR of≤1+ at
discharge. Followup data showed that surgical option after
percutaneous repair was preserved (32 patients had mitral
valve surgery during the 3.2 years after clip procedures; in
case of planned mitral repair, successful repair was obtained
in 84%) [64].
Among the successfully treated patients, freedom from
death, mitral valve surgery, and MR >2+ at 12 months were
66%. Overall survival was 90.1%, at 3 years. No diﬀerences
were observed in terms of acute results and durability
between patients with degenerative and functional MR [64].
The results of phase II of the study (EVEREST II),
which compared standard surgical repair to percutaneous
edge-to-edge mitral repair (randomization 2:1 MitraClip to
surgery), showed an incidence of major adverse events at
30 days (death, stroke, reoperation of MV, urgent/emergent
cardiovascular surgery, myocardial infarction, renal failure,
deep-wound infection, ventilation >48 hours, new onset
permanent atrial ﬁbrillation, septicemia, gastrointestinal
complication requiring surgery, and transfusions ≥2 units)
of 9.6% for the clip and of 57% for surgical MV repair.
Clinical success rate (freedom from death, MV surgery or re-
operation for MV dysfunction, and MR >2+) at 12 months
was 72% for the clip and 88% for surgical MV repair [65].
TheseresultsconﬁrmedthattheMitraClipprocedureisasafe
and eﬀective therapeutic option for selected patients with
signiﬁcant MR.
10. OurInitialExperienceinHigh-RiskPatients
In our Institution, 28 patients with severe MR have been
treated using the Mitraclip. 22 patients had functional MR
(FMR) and 6 patients had degenerative MR. Procedures
were performed under general anesthesia, using live 3D
transesophagealechocardiography.Meanagewas67.9 ±14.4
years and mean EF was 35% ± 20% (25% ± 7% in FMR
patients). All patients had severe central MR, dilated ventri-
cles (mean DTD 67 ± 6mm), and pulmonary hypertension
(PAPs was 45 ± 21mmHg). Mean logistic EuroSCORE was
23.9 ±15.5.In17patientstherewastheneedofasecondclip.
Median stay in the ICU and in the general ward was 1 and
5 days, respectively. Postprocedural course was complicated
by low cardiac output requiring inotropes in 6 patients
(21.4%), acute renal insuﬃciency in 3 patients (10.7%),
hemopericardium in 1 patient (3.5%), need of IABP in 2
patients (7.1%), and need of hemotransfusions in 3 patients
(10.7%).Atdischarge,2patients(7.1%)hadnoMR(0+/4+),
21 patients (75%) had mild (1+/4+) MR, and 5 patients
(17.8%) had moderate (2+/4+) MR.
11. Other Percutaneous MV Repair Procedures
Several alternative percutaneous procedures for the treat-
ment of the MV are being evaluated in preclinical studies.
The coronary sinus annuloplasty is based on the close
anatomical relation of the coronary sinus with the posterior
mitral annulus, and several devices exist for this approach:
the aim is to place devices in the coronary sinus to push
against the posterior portion of mitral annulus, in order
to improve the coaptation of the leaﬂets. Although success
in animals has been observed, human trials have presented
more diﬃculties, likely because often the coronary sinus,
which is an atrial structure, is not in the same plane as the
mitral annulus. Moreover, the circumﬂex coronary arteryCardiology Research and Practice 7
Table 3: Procedural and in-hospital results of patients submitted to trans-apical and trans-axillary TAVI Approach in our Institution.
Trans-apical Trans-axillary
Patients (n)1 5 1 5
Hospital stay (days), mean ± SD 15.8 ± 4.8 8.7 ± 1
Procedural success, n (%) 13 (86.6) 14 (93.3)
Need for permanent pacemaker, n (%) 3 (20) 1 (6.7)
Neurological events, n (%) 1 (6.7) 1 (6.7)
Acute renal failure requiring CVVH, n (%) 4 (26.6) 2 (13.3)
30-day clinical outcome
Death, n (%) 2 (13.3) 0
Cardiac death, n (%) 2 (13.3) 0
LVEF (%), mean ± SD 49.67 ± 10.4 52.73 ± 10.1
Six-month cumulative clinical outcome
Death, n (%) 4 (26.6) 2 (18.2)
Cardiac death, n (%) 4 (26.6) 1 (9.1)
LVEF (%), mean ± SD 56.22 ± 4.12 60.23 ± 3.45
SD: standard deviation; CVVH: continuous venovenous hemoﬁltration; LVEF: left ventricle ejection fraction.
or its branches may lie between the mitral annulus and
the coronary sinus, and the distance between the coronary
sinusandtheposteriormitralannulusincreaseswithchronic
ischemic MR because of the ongoing remodeling process
[66–68].
The most promising coronary sinus annuloplasty device
is the CARILLON Mitral Contour System (Cardiac Dimen-
sions, Inc., Kikland, Wash), which uses 2 self-expanding
nitinol anchors connected by a wire: the distal coronary
sinus anchor is deployed, then manual tension is applied to
the connecting wire and the proximal anchor is deployed,
obtaining a shortening of the mitral annular dimension.
The tension on the device can be adjusted before the ﬁnal
release. The multicenter AMADEUS trial suggested an acute
reduction in MR by a mean of 1 grade with the modiﬁed
CARILLON XE device [69, 70].
Other techniques are based on the concept of moving
the ventricle, rather than the annulus, to increase leaﬂet
coaptationandeliminatefunctionalMR.TheCoapsysdevice
(Myocor, Inc., MN, USA) employs a transventricular splint
withpadsontheoutersurfaceoftheleftventricle.Inanopen
chest, this can be placed without cardiopulmonary bypass
under direct echocardiographic guidance. Pads attached to
each end of the splint are tightened to pull the ventricle
into the region of the papillary muscles and also to move
the posterior leaﬂet to better coapt with the anterior leaﬂet.
Initial studies with the open-chest Coapsys system showed
encouraging results [71–73].
The i-Coapsys device performs the same role but can
be delivered in a minimally invasive procedure with ﬂuoro-
scopic guidance [74].
Another ﬁeld of application of percutaneous procedures
for MR is the correction of a paravalvular leak following
surgical MV replacement. When the periprosthetic leak
is haemodynamically relevant, a percutaneous treatment
may oﬀer an alternative to the redo surgery in high-risk
patients. Several diﬀerent types of devices that have not been
speciﬁcally designed for this purpose may be used (usually
coilsforverysmalldefects,patentductusdevicesformedium
defectsandatrialseptaloccludersforlargedefects).Resultsof
transcatheter mitral paravalvular leak have achieved variable
success rates, with a reported initial success rate of 60%
to 90% and a need for repeat intervention of about 40%
[21, 75–77].
The use of advanced image guidance with 3D echocar-
diographycouldenhancethetechnicalsuccessrate.Themost
important limitation remains the use of preexisting non
speciﬁc devices.
12. Limitations and Potential of Percutaneous
TreatmentofHeartValveDisease
With regard to TAVI, the pending questions concern mainly
safety and long-term durability. Using it in patients who
are good surgical candidates seems to be still premature.
Thus, TAVI should currently be restricted to patients at
high surgical risk or with contraindications for conventional
surgery. The emerging concept of valve-in-valve may provide
a feasible treatment option if and when currently implanted
percutaneous aortic valves deteriorate. Moreover, with the
advent of TAVI procedures, a degenerated bioprosthesis
can now be replaced less invasively and perhaps with less
risk using the transcatheter valve implantation techniques.
Therefore, current guidelines for choosing the type of valve
prosthesis may indeed require a revision.
With regard to MV repair using the Mitraclip, the surgi-
cal experience with Alﬁeri edge-to-edge technique indicates
that signiﬁcant MR recurs if the procedure is not associated
to an annuloplasty (need for reoperation 30% at 5 years),
especially in presence of a dilated mitral annulus [78–80],
so the long-term results of this technique have still to be
evaluated.
Percutaneous MV repair is attractive and should be
considered in all patients with functional MR (ischemic
or dilatative) at high surgical risk due to advanced age,8 Cardiology Research and Practice
concomitant comorbidities, or advanced heart failure, espe-
cially in presence of depressed EF, right ventricular dysfunc-
tion, or severe pulmonary hypertension. The main obstacles
totheextensionofthistechniqueinhigh-riskpatientsarethe
limited anatomical eligibility and the long learning curve for
the operators.
Another emerging ﬁeld of application of percutaneous
MV repair is the correction of simple degenerative MR
in young patients. The goal of modern MV valve surgery,
in fact, is to obtain excellent long-term results using an
approach as little as possible invasive, such as miniinvasive
or robotic surgery. The main purpose is the attempt to
totally neutralize the disease, obtaining a survival and a
quality of life comparable to an age-matched population.
If the operation is performed by conventional surgery, for
example, in a young female patient, the disease cannot be
considered neutralized, because of the persistence of the
scar: neutralizing the disease concerns also this aspect. This
consideration may justify the use of percutaneous MV repair
in young patients with simple MV prolapse, providing that
percutaneous edge-to-edge does not preclude surgical mitral
repair in case of failure of the percutaneous repair [81,
82]. As long as the percutaneous procedure is safe, even if
success rate is lower than that of surgery, patients with failed
percutaneous repairs are still candidates for surgical repair.
Therefore, transcatheter therapy may temporarily delay or
avoid the need for surgical intervention.
13. Conclusions
Transcatheteraorticandmitralvalveproceduresareevolving
very rapidly and are currently a therapeutic modality for
the patients with severe valvular disease who are unsuitable
for surgery because of technical/anatomical issues or too
high-estimated surgical risk. Several clinical trials, including
randomized studies between surgical and percutaneous
treatment, are currently ongoing and in the near future the
indications for these procedures likely will be extended to
patients who are good candidates for surgery.
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